Episode Summary
John shares our take on the first half of May which includes the proposal by The Centers for Medicare and Medicaid Services (CMS) to scale back its quality measures for fiscal year 2019 and the current administration’s “blueprint” to tackle soaring prescription drug prices.
Episode Notes
John shares our take on the first half of May which includes the proposal by The Centers for Medicare and Medicaid Services (CMS) to scale back its quality measures for fiscal year 2019 and the current administration’s “blueprint” to tackle soaring prescription drug prices.
- CMS is looking to reduce the number of quality measures across the five quality and value-based purchasing programs for its FY 2019 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Acute Care Hospital (LTCH) Prospective Payment System.
- President Trump announced his much anticipated proposal to control prescription drug pricing. In his remarks in the White House Rose Garden, Trump said, “The drug lobby is making an absolute fortune at the expense of American consumers.”
About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.
CONNECT WITH US:
🌐 Follow Health Care Rounds on LinkedIn
🌐 Follow Darwin Research Group on LinkedIn
📺 Watch Health Care Rounds on YouTube
⚙️ Health Care Rounds is produced by Grippi Media
Recommended Next
Subscribe to Our Take
Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.
